Identification of immunological predictors of COVID-19 clinical outcomes

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: Andrea  Lisco
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $22,511
Funding agency: National Institute of Allergy and Infectious Diseases

The extraordinarily wide spectrum of clinical manifestations associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, ranging from completely asymptomatic to fatal disease, represent an unexpected and unexplained clinical feature for an emerging highly contagious novel human pathogen. Host factors implicated in the innate or adaptive response to SARS-Cov2 as well as comorbidities or yet unidentified predictor are likely to be associated with such broad spectrum of clinical outcomes.
In collaboration with a network of southern Italian medical centers (Bari and Foggia) we have collected de-identified clinical data and biological specimens from over 300 individuals with asymptomatic infection (as identified by SARS-COv2 serological screening for blood donation), mild, moderate, severe or critical COVID-19 diseases to analyze the genetic and immunological correlates of these clinical outcomes in a collaborative project with other NIAID intramural investigators.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Biological><Biological Markers><Blood Donations><Blood Plasma><Blood Screening><COVID disease severity><COVID severity><COVID-19><COVID-19 disease severity><COVID-19 infection><COVID-19 severity><COVID-19 virus><COVID19><COVID19 disease severity><COVID19 infection><COVID19 severity><COVID19 virus><CV-19><CV19><Clinical><Clinical Data><CoV-2><CoV2><Collaborations><Disease><Disorder><Gene variant><Genetic><Goals><Host Factor><Host Factor Protein><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Individual><Infection><Integration Host Factors><Investigators><Medical center><NIAID><National Institute of Allergy and Infectious Disease><Outcome><Plasma><Plasma Serum><Research Personnel><Research Specimen><Researchers><Reticuloendothelial System, Serum, Plasma><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 disease severity><SARS-CoV-2 infection><SARS-CoV-2 severity><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serology><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Specimen><Wuhan coronavirus><allele variant><allelic variant><bio-markers><biologic marker><biomarker><clinical predictors><co-morbid><co-morbidity><comorbidity><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 disease severity><coronavirus disease 2019 infection><coronavirus disease 2019 severity><coronavirus disease 2019 virus><coronavirus disease severity><genetic variant><genomic variant><hCoV19><human pathogen><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><nCoV2><novel><respiratory><response><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 severity>